[1]聂兴玉,张铁耀,郝昌.垂体腺瘤组织miR-26b-5p表达与术后复发的关系[J].中国临床神经外科杂志,2022,27(06):458-460463.[doi:10.13798/j.issn.1009-153X.2022.06.008]
　NIE Xing-yu,ZHANG Tie-yao,HAO Chang.Expression of miR-26b-5p in pituitary adenoma tissues and its relationship with postoperative recurrence[J].,2022,27(06):458-460463.[doi:10.13798/j.issn.1009-153X.2022.06.008]
点击复制

垂体腺瘤组织miR-26b-5p表达与术后复发的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年06期
页码:
458-460463
栏目:
论著
出版日期:
2022-06-30

文章信息/Info

Title:
Expression of miR-26b-5p in pituitary adenoma tissues and its relationship with postoperative recurrence
文章编号:
1009-153X(2022)06-0458-03
作者:
聂兴玉; 张铁耀; 郝昌
457003 河南，濮阳市中医医院神经外科（聂兴玉、张铁耀、郝昌）
Author(s):
NIE Xing-yu;  ZHANG Tie-yao;  HAO Chang
Department of Neurosurgery, Puyang Hospital of Traditional Chinese Medicine, Puyang 457003, China
关键词:
垂体腺瘤; miR-26b-5p; 术后复发; 危险因素
Keywords:
Pituitary adenomas;  miR-26b-5p;  Postoperative recurrence;  Risk factors
分类号:
R739.41;Q786
DOI:
10.13798/j.issn.1009-153X.2022.06.008
文献标志码:
A
摘要:
目的 探讨微小核糖核酸-26b-5p（miR-26b-5p）与垂体腺瘤术后复发的关系。方法 收集2018年1月~2020年1月手术切除的124例垂体腺瘤组织，采用qRT-PCR检测miR-26b-5p相对表达水平。术后随访2年，利用多因素logistic回归模型分析垂体腺瘤术后复发的危险因素，绘制ROC曲线分析miR-26b-5p评估垂体腺瘤术后复发的效果。结果 124例中，术后复发34例，复发率为27.42%（34/124）。复发垂体腺瘤miR-26b-5p相对表达量（1.25±0.43）明显低于非复发垂体腺瘤[（1.87±0.49）；P<0.001]。多因素logistic回归分析显示，miR-26b-5p低表达是术后复发的独立危险因素（OR=1.232；95% CI 1.058~3.524；P<0.001）。ROC曲线分析显示，miR-26b-5p表达水平评估垂体腺瘤术后复发的曲线下面积为0.841（95% CI 0.767~0.915；P<0.001），最佳截断值为1.518，敏感度为84.80%，特异度为81.00%。结论 复发垂体腺瘤的miR-26b-5p表达水平明显下降，miR-26b-5p表达变化与术后复发密切相关，对评估垂体腺瘤术后复发有一定的价值。
Abstract:
Objective To investigate the expression of miR-26b-5p in pituitary adenoma tissues and its relationship with postoperative recurrence. Methods The expression of miR-26b-5p was detected using qRT-PCR in pituitary adenoma tissues obtained from 124 patients who underwent surgery from January 2018 to January 2020. All the patients were followed up for 2 years. Multivariate logistic regression model was used to analyze the risk factors of postoperative recurrence of pituitary adenoma. Receiver operating characteristic (ROC) curve was used to analyze the value of miR-26b-5p to assess postoperative recurrence. Results Of the 124 patients, 34 patients recurred after operation, and the recurrence rate was 27.42% (34/124). The relative expression of miR-26b-5p in recurrent pituitary adenomas (1.25±0.43) was significantly lower than that (1.87±0.49) in non-recurrent pituitary adenomas (P<0.001). Multivariate logistic regression analysis showed that low expression of miR-26b-5p was an independent risk factor for postoperative recurrence (OR=1.232; 95% CI 1.058~3.524; P<0.001). ROC curve analysis showed that the area under the curve of miR-26b-5p expression level in evaluating the postoperative recurrence of pituitary adenoma was 0.841 (95% CI 0.767~0.915; P<0.001), with a sensitivity of 84.80% and a specificity of 81.00%. Conclusions The expression level of miR-26b-5p in recurrent pituitary adenoma is significantly decreased, and the change of miR-26b-5p expression is closely related to postoperative recurrence, which has a certain value in evaluating postoperative recurrence of pituitary adenoma.

参考文献/References:

[1] Olsson DS, Bryngelsson IL, Ragnarsson O. Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study [J]. Pituitary, 2017, 20(2): 218-224.
[2] Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal[J]. Endocrrelat Cancer, 2017, 24(4): C5-C8.
[3] 袁仙仙，朱惠娟，潘　慧. 肿瘤免疫学在垂体瘤发病机制中的研究进展[J]. 国际内分泌代谢杂志，2019，39（1）：61-64.
[4] 段家峰，张秋娟，施　扬，等. miRNA与垂体瘤发病机制关系的研究进展[J]. 齐鲁医学杂志，2016，31：240-241.
[5] 邱　锋，王　荟，龚　立，等. miR-26b-5p通过抑制REST表达调节胶质瘤细胞生长和侵袭[J]. 医学分子生物学杂志，2020，17（1）：40-45.
[6] Jia CM, Tian YY, Quan LN, et al. miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1 [J]. Pathol Res Pract, 2018, 214(9): 1388-1394.
[7] 中国垂体腺瘤协作组，中华医学会神经外科学分会. 中国复发性垂体腺瘤诊治专家共识（2019）[J]. 中华医学杂志，2019，99（19）：1449-1453.
[8] 母义明. 垂体瘤诊治进展[J]. 解放军医学杂志，2017，42（7）：576-582.
[9] 巴一旭，杨　光，李国忠，等. 垂体腺瘤相关抑癌基因的研究进展[J]. 中国微侵袭神经外科杂志，2017，22：331-334.
[10] 刘　放，高晓健，陆　霞，等. miR-26家族与肿瘤关系的研究进展[J]. 生命科学，2014，26（11）：1222-1228.
[11] Wang Y, un B, Sun H, et al. Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p [J]. Tumour Biol, 2016, 37(8): 10965-10979.
[12] Fan F, Lu J, Yu W, et al. MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7 [J]. Oncol Lett, 2018, 15(1): 386-392.
[13] Vicchio TM, Aliquo F, Ruggeri RM, et al. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior [J]. J Endocrinol Invest, 2020, 43(1): 947-958.
[14] 赵红阳，赵曾辉，黄任萱，等. Ki-67指数对垂体腺瘤复发的临床意义[J]. 中国实验诊断学，2020，24（11）：92-94.
[15] 吕华荣，胡　玮，胡　胜，等. 垂体瘤内镜单侧鼻蝶入路的术后并发症及复发影响因素分析[J]. 神经损伤与功能重建，2017，12（2）：172-174.
[16] 李　兵，张溢华，黄　平，等. 垂体腺瘤术后复发的危险因素分析[J]. 中国临床神经外科杂志，2020，25（7）：436-438.
[17] 曹文红. 过表达miR-26b-5p抑制HMGA1参与卵巢癌细胞上皮间质转化的机制[J]. 武警医学，2019，30（9）：760-763.

相似文献/References:

[1]余龙洋　李亚楠　周　宇　戴冬伟　曹依群　岳志健.垂体腺瘤经蝶术后并发蛛网膜下腔出血的临床分析 （附6例报道）[J].中国临床神经外科杂志,2016,(06):372.[doi:10.13798/j.issn.1009-153X.2016.06.018]
[2]王国良　高　寒　张小鹏　公方和　李天栋.89例垂体腺瘤的手术治疗体会[J].中国临床神经外科杂志,2016,(07):435.[doi:10.13798/j.issn.1009-153X.2016.07.016]
[3]王亚平　贾晓雄　王　珺　王林林　谭溢涛　马德得　夏鹤春.神经内镜下与显微镜下经鼻蝶入路手术切除垂体腺瘤的疗效对比分析[J].中国临床神经外科杂志,2016,(03):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
　WANG Ya-ping,JIA Xiao-xiong,WANG-Jun,et al.Resection of pituitary adenomas by endoscopic and microscopic surgery via transnasal transsphenoidal approach: a comparative analysis[J].,2016,(06):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
[4]张海红　马　磊　张　威　郭　康　衡立君　贾　栋.垂体腺瘤MRI特征与视觉功能损害的关系分析[J].中国临床神经外科杂志,2016,(01):27.[doi:10.13798/j.issn.1009-153X.2016.01.010]
　ZHANG Hai-hong,MA Lei,ZHANG Wei,et al.Analysis of MRI characteristics and visual function in patient with pituitary adenomas[J].,2016,(06):27.[doi:10.13798/j.issn.1009-153X.2016.01.010]
[5]王先祥　张义泉　李庆新　王　斌　 肖　瑾　张　科.经单鼻孔蝶窦入路神经内镜下切除垂体腺瘤[J].中国临床神经外科杂志,2015,(12):715.[doi:10.13798/j.issn.1009-153X.2015.12.004]
　WANG Xian-xiang,ZHANG Yi-quan,LI Qing-xin,et al.Endoscopic endonasal transsphenoidal surgery for pituitary adenomas[J].,2015,(06):715.[doi:10.13798/j.issn.1009-153X.2015.12.004]
[6]马　涛　徐　韬.经蝶入路内镜手术与显微手术治疗垂体腺瘤疗效的Meta分析[J].中国临床神经外科杂志,2015,(12):748.[doi:10.13798/j.issn.1009-153X.2015.12.015]
[7]雷　霆.注重基础训练和知识更新，不断提高垂体腺瘤诊疗水平[J].中国临床神经外科杂志,2015,(10):577.[doi:10.13798/j.issn.1009-153X.2015.10.001]
[8]闫　进　李　松　杨　辉.1H-MRS对卵泡刺激素免疫阳性垂体腺瘤的诊断和预后评估的价值[J].中国临床神经外科杂志,2015,(10):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
　YAN Jin,LI Song,YANG Hui..Value of 1H-MRS to diagnosis and assessment of prognoses in patients with non-functioning gonadotroph adenomas[J].,2015,(06):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
[9]夏为民　邵耐远　唐　科.神经内镜辅助经鼻蝶入路手术治疗急性垂体腺瘤卒中[J].中国临床神经外科杂志,2015,(07):437.[doi:10.13798/j.issn.1009-153X.2015.07.020]
[10]王齐齐　陈　俊　王焕明　胡　飞.脊索瘤合并垂体腺瘤1例[J].中国临床神经外科杂志,2015,(07):448.[doi:10.13798/j.issn.1009-153X.2015.07.025]

备注/Memo

备注/Memo:
（2022-03-16收稿，2022-05-10修回）
更新日期/Last Update: 2022-07-31